Novartis, DNDi to collaborate on the development of a new drug for Visceral Leishmaniasis

SWITZERLAND – Novartis and the Drugs for Neglected Diseases initiative (DNDi), have signed a collaboration and licence agreement to jointly develop LXE408, as a potential new oral treatment for visceral leishmaniasis, one of the world’s leading parasitic killers. Visceral leishmaniasis, also known as kala-azar, is the most serious form of leishmaniasis, causing fever, weight loss, spleen and liver enlargement, and if left untreated, death. A joint statement by the two companies described LXE408 as “a first-in-class compound, discovered at Novartis with financial support from the Wellcome Trust.” Within the scope…

Read More